Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2020, Vol. 34 ›› Issue (3): 26-31.doi: 10.6040/j.issn.1673-3770.1.2020.029

Previous Articles     Next Articles

Advances in molecular mechanisms of anaplastic thyroid cancer

QING Xiaoyan1,XU Yiquan2Overview,LI Chao3Guidance   

  1. 1. Department of Oncology, Chengdu Seventh People's Hospital, Chengdu 610041, Sichuan, China;
    2. Department of Anesthesiology Medical Center, Sichuan Cancer Hospital & Institute, the Affiliated Cancer Hospital School of Medicine, University of Electronic Science and Technology, Chengdu 610041, Sichuan, China;
    3. Department of Head and Neck Surgery, Sichuan Cancer Hospital & Institute, the Affiliated Cancer Hospital School of Medicine, University of Electronic Science and Technology, Chengdu 610041, Sichuan, China
  • Online:2020-05-20 Published:2020-06-29

Abstract: Anaplastic thyroid cancer(ATC)is a rare invasive thyroid tumor associated with rapid progression and poor prognosis. Currently, there is no effective treatment or early diagnosis. Some scholars have shown that the poor prognosis of ATC is due to the early mutation and invasive growth of the tumor; consequently, new directions in research involve the driving mutation of the pathogenesis of ATC and targeted drug therapies. Different molecular pathways related to tumor progression are involved in ATC. Some scholars have explored the implementation of new therapies that act on these molecular pathways to improve patients' quality of life. The research results on the molecular structural characteristics of ATC bring hope for new targeted therapies. The new molecular mechanisms will help us discover more potential therapeutic targets. We have reviewed the recent research on the molecular mechanisms of ATC.

Key words: Anaplastic thyroid carcinoma, Invasive malignancy, Molecular mechanism, Genes, Targeted therapy

CLC Number: 

  • R739.91
[1] 宋晓宇, 宋西成. 缺氧诱导因子-1α在甲状腺癌中的调节机制[J]. 山东大学耳鼻喉眼学报, 2019, 33(2): 136-138, 148. doi:10.6040/j.issn.1673-3770.0.2018.317. SONG Xiaoyu, SONG Xicheng. Research progress on the regulation of HIF-1α expression in thyroid carcinoma[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(2): 136-138, 148. doi:10.6040/j.issn.1673-3770.0.2018.317.
[2] 中华人民共和国国家卫生健康委员会. 甲状腺癌诊疗规范(2018年版)[J]. 中华普通外科学文献(电子版), 2019, 13(1): 1-15. doi:10.3877/cma.j.issn.1674-0793.2019.01.001.
[3] Zheng JX, Cheng X, Xu SC, et al. Diallyl trisulfide induces G2/M cell-cycle arrest and apoptosis in anaplastic thyroid carcinoma 8505C cells[J]. Food Funct, 2019, 10(11): 7253-7261. doi:10.1039/c9fo00646j.
[4] Araque KA, Gubbi S, Klubo-Gwiezdzinska J. Updates on the management of thyroid cancer[J]. Horm EtMetab, 2020,10. doi:10.1055/a-1089-7870.
[5] Hugen N, Sloot YJE, Netea-Maier RT, et al. Divergent metastatic patterns between subtypes of thyroid carcinoma results from the nationwide Dutch pathology registry[J]. J Clin Endocrinol Metab, 2020, 105(3): dgz078. doi:10.1210/clinem/dgz078.
[6] Jiao C, Li L, Zhang P, et al. REGγ ablation impedes dedifferentiation of anaplastic thyroid carcinoma and accentuates radio-therapeutic response by regulating the Smad7-TGF-β pathway[J]. Cell Death Differ, 2020, 27(2): 497-508. doi:10.1038/s41418-019-0367-9.
[7] Ma YH, Cang SD, Li GQ, et al. Integrated analysis of transcriptome data revealed MMP3 and MMP13 as critical genes in anaplastic thyroid cancer progression[J]. J Cell Physiol, 2019, 234(12): 22260-22271. doi:10.1002/jcp.28793.
[8] Kohler H, Latteyer S, HönesGS, et al. Increased anaplastic lymphoma kinase activity induces a poorly differentiated thyroid carcinoma in mice[J]. Thyroid, 2019, 29(10): 1438-1446. doi:10.1089/thy.2018.0526.
[9] Wang Q, Sui GQ, Wu XL, et al. A sequential targeting nanoplatform for anaplastic thyroid carcinoma theranostics[J]. Acta Biomater, 2020, 102: 367-383. doi:10.1016/j.actbio.2019.11.043.
[10] Weber F, Junger H, Werner JM, et al. Increased cytoplasmatic expression of cancer immune surveillance receptor CD1d in anaplastic thyroid carcinomas[J]. Cancer Med, 2019, 8(16): 7065-7073. doi:10.1002/cam4.2573.
[11] Schürch CM, Roelli MA, Forster S, et al. Targeting CD47 in anaplastic thyroid carcinoma enhances tumor phagocytosis by macrophages and is a promising therapeutic strategy[J]. Thyroid, 2019, 29(7): 979-992. doi:10.1089/thy.2018.0555.
[12] Ferrari SM, Elia G, Ragusa F, et al. Novel treatments for anaplastic thyroid carcinoma[J]. Gland Surg, 2020, 9(Suppl 1): S28-S42. doi:10.21037/gs.2019.10.18.
[13] Hao Z, Wang P. Lenvatinib in Management of Solid Tumors[J]. Oncologist,2020,25(2):e302-e310. doi: 10.1634/theoncologist.2019-0407.
[14] Stenman A, Hellgren LS, Jatta K, et al. Metastatic anaplastic thyroid carcinoma in complete remission: morphological, molecular, and clinical work-up of a rare case[J]. Endocr Pathol, 2020, 31(1): 77-83. doi:10.1007/s12022-020-09606-5.
[15] Paulsson JO, Backman S, Wang N, et al. Whole-genome sequencing of synchronous thyroid carcinomas identifies aberrant DNA repair in thyroid cancer dedifferentiation[J]. J Pathol, 2020, 250(2): 183-194. doi:10.1002/path.5359.
[16] Calabrese G, Dolcimascolo A, Caruso G, et al. MiR-19a is involved in progression and malignancy of anaplastic thyroid cancer cells[J]. Onco Targets Ther, 2019, 12: 9571-9583. doi:10.2147/OTT.S221733.
[17] Pellecchia S, Sepe R, Decaussin-Petrucci M, et al. The long non-coding RNA Prader willi/angelman region RNA5(PAR5)is downregulated in anaplastic thyroid carcinomas where it Acts as a tumor suppressor by reducing EZH2 activity[J]. Cancers(Basel), 2020, 12(1): E235. doi:10.3390/cancers12010235.
[18] Credendino SC, Bellone ML, Lewin N, et al. A Cernacircuitry involving the long noncoding RNA Klhl14-AS, Pax8, and Bcl2 drives thyroid carcinogenesis[J]. Cancer Res, 2019, 79(22): 5746-5757. doi:10.1158/0008-5472.CAN-19-0039.
[19] Wächter S, Vorländer C, Schabram J, et al. Anaplastic thyroid carcinoma: changing trends of treatment strategies and associated overall survival[J]. Eur Arch Otorhinolaryngol, 2020, 277(5): 1507-1514. doi:10.1007/s00405-020-05853-8.
[20] Nikitski AV, Rominski SL, Condello V, et al. Mouse model of thyroid cancer progression and dedifferentiation driven by STRN-ALK expression and loss of p53: evidence for the existence of two types of poorly differentiated carcinoma[J]. Thyroid, 2019, 29(10): 1425-1437. doi:10.1089/thy.2019.0284.
[21] Lin B, Ma HQ, Ma MG, et al. The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis[J]. Am J Transl Res, 2019, 11(9): 5888-5896.
[22] Yan P, Su ZJ, Zhang ZH, et al. LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR?9?5p and regulating SPAG9 expression[J]. Int J Oncol, 2019, 55(5): 988-1002. doi:10.3892/ijo.2019.4868.
[23] Revilla G, Pons MP, Baila-Rueda L, et al. Cholesterol and 27-hydroxycholesterol promote thyroid carcinoma aggressiveness[J]. Sci Rep, 2019, 9(1): 10260. doi:10.1038/s41598-019-46727-2.
[24] Zhong ZM, Chen X, Qi X, et al. Adaptor protein LNK promotes anaplastic thyroid carcinoma cell growth via 14-3-3 ε/γ binding[J]. Cancer Cell Int, 2020, 20: 11. doi:10.1186/s12935-019-1090-9.
[25] Pereira M, Williams VL, Hallanger Johnson J, et al. Thyroid cancer incidence trends in the United States: association with changes in professional guideline recommendations[J]. Thyroid, 2020,3. doi:10.1089/thy.2019.0415.
[26] Minna E, Brich S, Todoerti K, et al. Cancer associated fibroblasts and senescent thyroid cells in the invasive front of thyroid carcinoma[J]. Cancers(Basel), 2020, 12(1): E112. doi:10.3390/cancers12010112.
[27] Haddad RI, Nasr C, Bischoff L, et al. NCCN guidelines insights: thyroid carcinoma, version 2.2018[J]. J Natl Compr Canc Netw, 2018, 16(12): 1429-1440. doi:10.6004/jnccn.2018.0089.
[28] Saini S, Tulla K, Maker AV, et al. Therapeutic advances in anaplastic thyroid cancer: a current perspective[J]. Mol Cancer, 2018, 17(1): 154. doi:10.1186/s12943-018-0903-0.
[29] Mirian C, Grnhj C, Jensen DH, et al. Trends in thyroid cancer: Retrospective analysis of incidence and survival in Denmark 1980-2014[J]. Cancer Epidemiol, 2018, 55: 81-87. doi:10.1016/j.canep.2018.05.009.
[30] Gunda V, Gigliotti B, Ndishabandi D, et al. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer[J]. Br J Cancer, 2018, 119(10): 1223-1232. doi:10.1038/s41416-018-0296-2.
[31] Ljubas J, Ovesen T, Rusan M. A systematic review of phase II targeted therapy clinical trials in anaplastic thyroid cancer[J]. Cancers(Basel), 2019, 11(7): E943. doi:10.3390/cancers11070943.
[1] LIN XiaoqinOverview,WU MiaoqinGuidance. Pathogenesis and treatment of idiopathic epiretinal membranes [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(2): 121-128.
[2] Yupeng SHEN,Qi SONG,Xiaoming LI. Etiology, molecular mechanisms, and treatment strategies of precancerous laryngeal lesions [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(4): 25-30.
[3] Huabin LI,Yuting LAI,Wenxiu JIANG. Endotypes and precision medicine in chronic sinusitis treatment [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(3): 9-13.
[4] Meiping LU,Lei CHENG. Current status of genetic research on allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(3): 36-41.
[5] Haijun LU,Ji LIU,Xiao DING. Progress in the comprehensive treatment for nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(2): 26-30.
[6] SUN Ziwen, CUI Hongwei, SUN Xiling, CHEN Chen, ZHANG Lu, HU Zhulin. SUN Ziwen1, CUI Hongwei2, SUN XilingEtiology, pathogenesis, and management of dry eye [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(2): 159-166.
[7] Yu ZHANG,Xicheng SONG. Advances in interaction mechanisms and treatment strategy between chronic rhinosinusitis with nasal polyp and asthma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(1): 49-52.
[8] WU Jing, LIU Yehai. Targeted therapy for head and neck squamous cell carcinoma [J]. J Otolaryngol Ophthalmol Shandong Univ, 2018, 32(5): 97-102.
[9] SUN Bin, GUO Bomin, KANG Jie, DENG Xianzhao, WU Bo, FAN Youben. Standardization of the diagnosis and treatment of anaplastic thyroid carcinoma. [J]. J Otolaryngol Ophthalmol Shandong Univ, 2017, 31(6): 16-20.
[10] ZHANG Ruxin. Prospect and progress of allergic rhinitis. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(4): 3-6.
[11] TENG Weiqiang, CHEN Xiaoping, ZHANG Yan, ZHOU Enhui, YAO Wenhao, LI Li. Study on single nucleotide polymorphisms of partial allergic rhinitis-associated haplotype module genes. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(4): 26-29.
[12] DU Xiangge, ZHANG Yingchun, YAN Xin, WANG Cui, ZHAO Bojun. In vitro study of the effect of Casein Kinase2 siRNA on anginogesis [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(3): 76-80.
[13] YANG Zi-chao, WANG Yu-liang. Etiology, mechanism of dye eye and advancement of traditional Chinese medicine in combination with western medicine for it [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(2): 91-93.
[14] ZHANG Chan-juan, LI Yan-zhong, WANG Yan. The relationship between brain derived neurotrophic factor and obstructive sleep apnea syndrome [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(1): 8-11.
[15] WANG Xiang, LIU Qiang-he. Progress of molecular mechanisms of presbycusis [J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(3): 79-82.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] LIN Bin,WANGHui-ge . Functional endoscopic sinus surgery, FESS[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2006, 20(6): 481 -487 .
[2] . [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2006, 20(1): 84 -87 .
[3] . [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2006, 20(2): 116 -118 .
[4] ZHOU Zi-ning,JIN Guo-wei . [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2006, 20(5): 462 -465 .
[5] GONG Lei,SUN Jie,XUE Zi-chao,LI Jing-hua,XUE Wei-guo . DNA analysis of the cell cycle in sino-nasal neoplasm[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(3): 193 -195 .
[6] CHEN Wen-wen . [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2006, 20(5): 472 -472 .
[7] ZHOU Bin,LI Bin . Endoscopic sinus surgery for 75 patients with chronic sinusitis and nasal polyps[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2006, 20(1): 24 -26 .
[8] YANG Changliang,HUANG Zhiwu,YAO Hangqi,ZHU Yong,SNU Yi . Study on auditory brainstem response[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2006, 20(1): 9 -13 .
[9] . [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2006, 20(1): 89 -89 .
[10] LUAN Jiangang,LIANG Chuanyu,WEN Yanjun,LI Jiong . Construction of RNAi expressing plasmid vector of pSIRENshuttle for EGFR gene silencing[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2006, 20(1): 4 -8 .